‘Weight’ & Watch: Indian Pharma Set To Enter Ozempic, Wegovy Market, But Swift Price Crash Unlikely
The Indian market for GLP-1 drugs has not fully opened yet due to unavailability and affordability issues. However, Indian drugmakers are gearing up to launch copycat weight-loss drugs as the patents for Novo Nordisk’s brands are set to expire. Experts anticipate a rise in demand for these drugs in India, considering the country’s high rates…
